Generated by AI
Silence Therapeutics Plc ADR is a biotechnology company focused on developing RNA-based medicines that use short interfering RNA, or siRNA, to regulate the activity of specific genes. Silence Therapeutics Plc ADR is working across hematology, cardiovascular disease, and rare diseases, with a pipeline that includes candidates designed to address blood disorders, complement-mediated renal conditions, and lipid-related cardiovascular conditions. The company’s research and development activities center on discovering and delivering novel RNA therapeutics that can silence disease-driving targets inside cells. Through its current product candidates and platform-driven approach, Silence Therapeutics Plc ADR plays a specialized role in the growing field of genetic medicine, where precision therapies are being developed for conditions with limited treatment options. The company is headquartered in London, United Kingdom.
Website12 Hammersmith Grove
London, W6 7AP
United Kingdom
The latest articles about SLN.
Summary of Oct 21's posts. Generated by AI.
Summary of Oct 19's posts. Generated by AI.
Summary of Oct 21's posts. Generated by AI.
Investors talking about SLN also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.